Expanding Vaccine Portfolio HIPRA's recent launch of YURVAC RHD and ongoing development of COVID-19 vaccines demonstrate a strong commitment to expanding its portfolio of innovative biologics, presenting opportunities to supply complementary vaccines for both veterinary and human health sectors.

International Presence With a solid presence in over 100 countries across five continents, HIPRA's global distribution network offers significant sales expansion potential for partners aiming to access diverse markets with advanced biotech products.

Technological Innovation Utilizing advanced tools such as genomic analysis, clinical trial collaborations, and molecular vaccine platforms positions HIPRA at the forefront of biotech innovation, opening avenues for joint research and licensing of cutting-edge vaccine technologies.

R&D Focus HIPRA’s extensive 50-year R&D experience and control over the entire value chain enable the development of specialized, high-demand biologics, creating opportunities to collaborate on custom vaccine solutions for emerging market needs.

Market Growth in Animal Health As a major player in the animal health industry alongside companies like Zoetis and Bayer, HIPRA is well-positioned to capitalize on the growing demand for veterinary vaccines and diagnostics driven by increased focus on livestock and pet health worldwide.